Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

National Institute for Health and Care Excellence (NICE) Issues Positive Guidance for Jazz Pharmaceuticals' Sunosi®▼ (solriamfetol) for the Treatment of Adults with Excessive Daytime Sleepiness (EDS) Caused by Narcolepsy

This image opens in the lightbox

News provided by

Jazz Pharmaceuticals plc

18 Nov, 2021, 16:55 GMT

Share this article

Share toX

Share this article

Share toX

Sunosi®▼(solriamfetol) is the first treatment for adults with excessive daytime sleepiness (EDS) caused by narcolepsy to receive a positive recommendation from NICE

Pivotal Phase 3 Treatment of Obstructive sleep apnoea and Narcolepsy Excessive Sleepiness (TONES) studies demonstrated the clinical effectiveness and safety profile of solriamfetol in people with narcolepsy. TONES 5 demonstrated that the clinical effects of solriamfetol were maintained long term

Positive NICE recommendation means solriamfetol will be available in England and Wales to adults with EDS caused by narcolepsy for whom modafinil and either dexamfetamine or methylphenidate  have not worked well enough or are not suitable

OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Document (FAD) recommending Sunosi®▼ (solriamfetol) for adults with excessive daytime sleepiness (EDS) caused by narcolepsy.1 Solriamfetol is recommended as an option for treating EDS in adults with narcolepsy with or without cataplexy. This is only if modafinil and either dexamfetamine or methylphenidate* have not worked well enough or are not suitable.1 

EDS is a defining clinical symptom of narcolepsy and is usually the first symptom to appear.2,3 EDS can interfere with every aspect of a person's life including their physical and mental health, relationships, employment, career, daily activities, social interactions and family life.4

"This decision increases treatment options for people with narcolepsy, creating more opportunity for them to access effective treatment sooner. This is a key aim of Narcolepsy UK's Charter as access to effective treatment can dramatically improve multiple aspects of people's lives including their education, working, family and social life," said Matt O'Neill, chair of trustees at Narcolepsy UK. "We welcome NICE's decision and the committee's recognition of the need for pragmatism when faced with limited evidence with which to compare the cost-effectiveness of treatments for rare diseases such as narcolepsy."

Dr Paul Reading, consultant neurologist at South Tees National Health Service (NHS) Foundation Trust, said: "NICE's recommendation to offer routine NHS access to solriamfetol gives clinicians a much-needed additional treatment option in the management of EDS in narcolepsy for adult patients. Solriamfetol is a once-daily, effective therapy with an interesting mechanism of action as a dual-acting dopamine and noradrenaline reuptake inhibitor."

Commenting on the recommendation, Simon Newton, general manager, UK and Ireland, at Jazz Pharmaceuticals, said: "We are delighted that by recommending Sunosi®▼, NICE has given a green light to the NHS to fund a treatment for EDS in adults with narcolepsy. NICE's recommendation marks an important milestone in our commitment to offer life-changing medicines that address unmet needs for people living with chronic, and often highly-debilitating, sleep disorders."

About Narcolepsy

Narcolepsy is a chronic, debilitating neurological disorder characterised by excessive daytime sleepiness (EDS) and an inability to regulate sleep-wake cycles normally.5 An estimated 30,000 people in the UK have narcolepsy.6,7 Patients with EDS due to narcolepsy experience sleep attacks and, despite fighting the urge to sleep, may unintentionally fall asleep for short periods.8,9 These sleep attacks may happen at inappropriate or potentially dangerous times such as during driving, cycling, eating, or mid-conversation.10

There is no cure for narcolepsy, therefore this EDS is lifelong and has a substantial negative impact on a person's ability to function psychologically, socially and professionally.6 Early access to effective treatment can transform lives and reduce the impact of narcolepsy on a person's physical and mental health.6

About Sunosi®▼(solriamfetol) 

Once-daily Sunosi®▼(solriamfetol) is indicated to improve wakefulness and reduce EDS in adult patients with narcolepsy with the approved doses of 75 mg or 150 mg daily. The NICE recommendation for solriamfetol is based on data from three studies in the Treatment of Obstructive sleep apnoea and Narcolepsy Excessive Sleepiness (TONES) clinical trial programme.1,11,12,13 The clinical trial programme for solriamfetol evaluated over 900 adults with EDS associated with narcolepsy or obstructive sleep apnoea (OSA). Solriamfetol demonstrated its superiority relative to placebo and was shown to maintain its effect after six months of use.11,12,13,14

For a full list of side effects and information on dosage and administration, contraindications and other precautions when using solriamfetol, please refer to the Summary of Product Characteristics, included with this press release, for further information: https://www.medicines.org.uk/emc/product/11016/smpc 
https://www.medicines.org.uk/emc/product/11017/smpc 

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries.

Jazz Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland, +353 1 697 2141

Jazz Investor Contact:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com 
Ireland, +353 1 634 3211 

* Methylphenidate is not licensed for the treatment of EDS due to narcolepsy in the UK

REFERENCES

  1. National Institute for Health and Care Excellence. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602] - Final Appraisal Document 2021. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10524/documents Last accessed: November 2021.
  2. Sahni, A.S., et al., Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects. Nat Sci Sleep, 2019. 11: p.241-252.
  3. Sateia, M.J., International classification of sleep disorders-third edition: highlights and modifications. Chest, 2014. 146(5): p.1387-1394.
  4. Narcolepsy UK. Narcolepsy Charter. 2019. Available from: https://www.narcolepsy.org.uk/sites/narcolepsy.org.uk/files/resources/files/NUK_Charter_v12%28withQR%29.pdf Last accessed: November 2021.
  5. National Institute of Neurological Disorders and Stroke. Narcolepsy fact sheet. 2018. Available from: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet  Last accessed: November 2021.
  6. National Health Service. Narcolepsy - Overview. 2019. Available from: https://www.nhs.uk/conditions/narcolepsy/  Last accessed: November 2021.
  7. Narcolepsy UK. About Narcolepsy. 2019. Available from: https://www.narcolepsy.org.uk/about-narcolepsy Last accessed: November 2021.
  8. Dauvilliers, Y., I. Arnulf, and E. Mignot, Narcolepsy with cataplexy. The Lancet, 2007. 369(9560): p.499-511.
  9. Committee on Sleep Medicine and Research (Board on Health Sciences Policy), Ch 3. Extent and Health Consequences of Chronic Sleep Loss and Sleep Disorders, in Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem, H.R. Colten and B.M. Altevogt, Editors. 2006, The National Academies Press,: Washington DC, USA.
  10. Peacock, J. and R. Benca, Narcolepsy: clinical features, co-morbidities & treatment. Indian Journal of Medical Research, 2010.131(2): p.338-349.
  11. Thorpy, M.J., et al., A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol, 2019. 85(3): p. 359-370.
  12. Malhotra, A., et al., Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep, 2020. 43(2).
  13. Strollo, P.J., Jr., et al., Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study. Chest, 2019. 155(2): p.364-374.
  14. European Medicines Agency. Sunosi: EPAR - Public Assessment Report (12/02/2020). 2020. Available from: https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf Last accessed: November 2021.

Logo - https://mma.prnewswire.com/media/1691994/Jazz_Pharma_Logo.jpg 

Modal title

Also from this source

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2025 and updated financial guidance for 2025. "In...

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

International Medical Approval

International Medical Approval

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.